Skip to main content
Premium Trial:

Request an Annual Quote

Illumina, French Hospitals Partner on Cancer Genomic Profiling Study

NEW YORK – Illumina said on Thursday that it has partnered with France's Jean Perrin Center at the Clermont-Ferrand University Hospital and its collaborators to study the clinical value of comprehensive genomic profiling, or CGP, in patients with late-stage cancer.

Under the terms of the agreement, researchers will use Illumina's TruSight Oncology 500 assay to explore cancer therapy options for patients with advanced melanoma, colorectal, breast, and lung cancers. The CELIA (comprehensive genomic profiling impact) study, led by the Jean Perrin Center with participation from Toulouse Oncopole and the Bordeaux University Hospital Center, will compare CGP in therapy selection to the current standard of care, including small panel tests.

In an email, Illumina said it expects the study will recruit approximately 300 patients, with an option to go up to 400.

French bioinformatics firm SeqOne Genomics will analyze data and generate clinical reports outlining treatment options and clinical trial eligibility. Illumina will provide sequencing reagents and biostatistics expertise.

Other details of the agreement were not disclosed.

"CGP is being increasingly used in cancer centers throughout Europe, including France. Our goal is to confirm the clear clinical utility in order to make next-generation sequencing for metastatic cancer more broadly included in European and national clinical guidelines," Frédérique Penault-Llorca, general director of the Jean Perrin Center and coordinator of the CELIA study, said in a statement. “Data from the CELIA study will add to the growing body of evidence on CGP, with the aim of accelerating the adoption of precision medicine for cancer patients."

Illumina's TruSight Oncology 500 assay analyzes 500 genes for mutations and other biomarkers to aid in precision oncology. Last month, Illumina partnered with the National Cancer Center Japan to use the assay in a study of nasopharyngeal carcinoma.

SeqOne closed a 20 million ($22.6 million) Series A financing round last month.

Evidence from the study will be used to support a precision medicine approach for patients with late-stage cancer within the French healthcare system, the partners said.